Profen and Gemtesa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Profen (ibuprofen) and Gemtesa (vibegron). Common drug interactions include urinary tract infection among females and hallucination among males.

The phase IV clinical study analyzes what interactions people have when they take Profen and Gemtesa. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Profen?

Profen has active ingredients of ibuprofen. It is often used in pain. eHealthMe is studying from 245,311 Profen users. Check the latest studies of Profen.

What is Gemtesa?

Gemtesa has active ingredients of vibegron. eHealthMe is studying from 2,648 Gemtesa users. Check the latest studies of Gemtesa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 20, 2026

27 people who take Profen and Gemtesa together, and have interactions are studied.

Profen and Gemtesa drug interactions.

What are the common drug interactions of Profen and Gemtesa, by gender? *:

female:

  1. Urinary tract infection
  2. Asthma
  3. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  4. Dizziness
  5. Fall
  6. Fibromyalgia (a long-term condition which causes pain all over the body)
  7. Migraine (headache)
  8. Multiple allergies (allergy to multiple agents)
  9. Hypertension (high blood pressure)
  10. Procedural pain

male:

  1. Hallucination (an experience involving the perception of something not present)
  2. Dizziness
  3. Restlessness (not able to rest)
  4. Confusional state
  5. Delusion (a false belief or opinion)
  6. Depression
  7. Disease progression
  8. Nonspecific reaction (unspecified reaction)
  9. Parkinson's disease
  10. Urinary retention postoperative

What are the common drug interactions of Profen and Gemtesa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Restlessness (not able to rest)

30-39:

n/a

40-49:

  1. Asthma
  2. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  3. Fibromyalgia (a long-term condition which causes pain all over the body)
  4. Migraine (headache)
  5. Multiple allergies (allergy to multiple agents)
  6. Hysterectomy

50-59:

  1. Abdominal distension
  2. Anxiety
  3. Asthenia (weakness)
  4. Cellulitis (infection under the skin)
  5. Conjunctivitis (pink eye)
  6. Eating disorder
  7. Fall
  8. Fungal infection
  9. Gastric infection (infection of stomach)
  10. Gastrointestinal disorder (functional problems of gastrointestinal tract)

60+:

  1. Dizziness
  2. Urinary tract infection
  3. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  4. Adverse drug reaction
  5. Alopecia (absence of hair from areas of the body)
  6. Balance disorder
  7. Bladder discomfort
  8. Blood folate decreased
  9. Blood pressure increased
  10. Bradycardia (abnormally slow heart action)

What are the existing conditions these people have? *

  1. Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 5 people, 18.52%
  2. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 14.81%
  3. High Blood Pressure: 3 people, 11.11%
  4. Drowsiness: 3 people, 11.11%
  5. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 11.11%
  6. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 11.11%
  7. Urinary Incontinence (inability to control the flow of urine and involuntary urination): 2 people, 7.41%
  8. Muscle Spasms (muscle contraction): 2 people, 7.41%
  9. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 7.41%
  10. Hypersensitivity: 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Profen and Gemtesa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Profen and Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Profen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Profen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemtesa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ibuprofen and vibegron (the active ingredients of Profen and Gemtesa, respectively), and Profen and Gemtesa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: